Structural Model and trans-Interaction of the Entire Ectodomain of the Olfactory Cell Adhesion Molecule  by Kulahin, Nikolaj et al.
Structure
ArticleStructural Model and trans-Interaction
of the Entire Ectodomain
of the Olfactory Cell Adhesion Molecule
Nikolaj Kulahin,1,2,3,4 Ole Kristensen,2 Kim K. Rasmussen,1,2 Lars Olsen,2 Patrik Rydberg,2 Bente Vestergaard,2
Jette S. Kastrup,2 Vladimir Berezin,1 Elisabeth Bock,1 Peter S. Walmod,1,* and Michael Gajhede2,*
1Protein Laboratory, Department of Neuroscience and Pharmacology, Faculty of Health Sciences, University of Copenhagen, DK-2200
Copenhagen N, Denmark
2Biostructural Research, Department of Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Copenhagen, DK-2100
Copenhagen O, Denmark
3ENKAM Pharmaceuticals A/S, DK-2100 Copenhagen O, Denmark
4Present address: Receptor Systems Biology Laboratory, Hagedorn Research Institute, DK-2820 Gentofte, Denmark
*Correspondence: psw@sund.ku.dk (P.S.W.), mig@farma.ku.dk (M.G.)
DOI 10.1016/j.str.2010.12.014SUMMARY
The ectodomain of olfactory cell adhesion molecule
(OCAM/NCAM2/RNCAM) consists of five immuno-
globulin (Ig) domains (IgI–V), followed by two fibro-
nectin-type 3 (Fn3) domains (Fn3I–II). A complete
structural model of the entire ectodomain of human
OCAM has been assembled from crystal structures
of six recombinant proteins corresponding to
different regions of the ectodomain. The model is
the longest experimentally based composite struc-
tural model of an entire IgCAM ectodomain. It
displays an essentially linear arrangement of IgI–V,
followed by bends between IgV and Fn3I and
between Fn3I and Fn3II. Proteins containing IgI–IgII
domains formed stable homodimers in solution and
in crystals. Dimerization could be disrupted in vitro
by mutations in the dimer interface region. In
conjunction with the bent ectodomain conformation,
which can position IgI–V parallel with the cell surface,
the IgI–IgII dimerization enables OCAM-mediated
trans-interactions with an intercellular distance of
about 20 nm, which is consistent with that observed
in synapses.
INTRODUCTION
Neural cell adhesionmolecules (CAMs) have adhesive properties
that are of major importance for the self-assembly of intercon-
nections between cells in the mammalian brain. Additionally,
they have many other functions related to cell-cell signaling
(reviewed in Shapiro et al., 2007). CAMs are divided into several
families, including the integrins, selectins, cadherins, and CAMs
of the immunoglobulin (Ig) superfamily (Juliano, 2002). CAMs are
generally multidomain proteins with the extracellular part
comprising domains in a modular arrangement. The molecular
mechanisms controlling the various functions of CAMs haveStructure 19, 20attracted much attention from the field of drug discovery. For
example, CAMs can be essential therapeutic targets for the
treatment of cancer or neurodegenerative diseases (Raveh
et al., 2009; Rice et al., 2005).
Mammalian forms of olfactory cell adhesion molecule (OCAM/
NCAM2/RNCAM) were cloned in 1997 (Alenius and Bohm, 1997;
Paoloni-Giacobino et al., 1997; Yoshihara et al., 1997). OCAM
exists in a transmembrane and a glycosylphosphatidylinositol-
anchored isoform resulting from alternative splicing of the tran-
script from a single gene (reviewed in Kulahin and Walmod,
2010). OCAM transcripts are found in several tissues (Paoloni-
Giacobino et al., 1997) including different regions of the brain
where it is believed to regulate neurite outgrowth, axonal guid-
ance, synapse formation, and the formation of dendritic bundles
(Hamlin et al., 2004; Ichinohe et al., 2003; Paoloni-Giacobino
et al., 1997). The expression of OCAM has been suggested to
potentially influence certain types of neurological diseases,
including autism (Molloy et al., 2005) and Down’s syndrome
(Paoloni-Giacobino et al., 1997), and studies also indicate that
the expression of OCAM can be changed in, for example, pros-
tate cancer cells (Edwards et al., 2005; Xu et al., 2001).
OCAM is a paralog of neural cell adhesion molecule 1
(NCAM1) (see Owczarek et al., 2009), and the extracellular part
of both proteins consists of five N-terminal Ig domains (IgI–V),
followed by two fibronectin type III domains (Fn3I–II) (Figure 1).
Cell aggregation studies have shown that OCAM mediates
homophilic trans-interactions, but the domains involved in the
interaction have not been identified. Additionally, in vitro binding
assays suggest that OCAM does not participate in heterophilic
interactions with NCAM1 (Yoshihara et al., 1997).
The molecular basis for homophilic interactions within the
IgCAMs has been investigated in, for example, the L1CAM family
(Haspel and Grumet, 2003) and DSCAM (Sawaya et al., 2008).
Within the NCAM family, the crystal structures of the N-terminal
Ig domains IgI–II (Kasper et al., 2000) and IgI–III (Soroka et al.,
2003) of NCAM1 have been determined (reviewed in Soroka
et al., 2010), and recently, the crystal structure of OCAM Ig1
was published (Rasmussen et al., 2008).
Structural models of the entire ectodomain only exist for rela-
tively short IgCAMs, such as P0 (one Ig domain), JAM1 (two Ig3–211, February 9, 2011 ª2011 Elsevier Ltd All rights reserved 203
Figure 1. Alignment of NCAM1 and OCAM Ectodomains
NCAM1_a, NCAM1_b, OCAM_a, and OCAM_b correspond to the crystal
structures of NCAM1 IgI–II (PDB code 1epf), NCAM1 IgI-III (PDB code 1qz1),
OCAM IgI-II (PDB code 2XY2), and OCAM IgI-III (PDB code 2wim), respec-
tively. The assignment of OCAM secondary-structure elements using the
dssp program (Kabsch and Sander, 1983) is shown below the sequences.
Residue numeration is shown for OCAM (Uniprot code O15394) above the
sequences. Residues involved in IgI–II dimer formation are colored blue or
red. Residues that are involved in IgI–II/IgI–II dimer formation and in making
hydrogen bonds or salt bridges are colored red. Furthermore, residues that
are buried more than 50% in the interface are underlined. Residues proposed
to be involved in the dimerization include residues giving positive contribution
to the interaction energy as defined in the PISA software (http://www.ebi.ac.
uk/msd-srv/prot_int/cgi-bin/piserver). N-linked glycosylation sites are marked
as N-glyc (present in both NCAM1 and OCAM), N-glyc* (present only in
NCAM1), and N-glyc# (present only in OCAM). N-linked glycosylation sites
polysialylated in NCAM1 IgV are marked as N-glyc and colored red. HBS indi-
cates the heparin-binding site in NCAM1 IgII (Lys152-Arg156, Val158, Ile159,
Lys161-Phe166, Gly185, Tyr187, and Glu190 in NCAM1; Uniprot code
P13591). VASE indicates the region in NCAM1 IgIV encoded by the VASE
exon, and Fn3I a helix indicates the a helix in NCAM1 Fn3I essential for IgV
polysialylation.
Structure
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204 Structure 19, 203–211, February 9, 2011 ª2011 Elsevier Ltd All rdomains), and SIRPa (three Ig domains) (Hatherley et al., 2009;
Prota et al., 2003; Shapiro et al., 1996). For longer IgCAMs, struc-
tures of ectodomain segments are available for TAG-1 (four out
of ten extracellular domains) and DSCAM (eight out of 16 extra-
cellular domains) (Mortl et al., 2007; Sawaya et al., 2008).
However, no structural models of the entire ectodomain of long
IgCAMs have been proposed.
Here, we present a structural model of the entire 700 amino
acid-long ectodomain of human OCAM, assembled from crystal
structures of six recombinant proteins with overlapping primary
sequences. This represents the longest experimentally based
composite structural model of the entire extracellular part of an
IgCAM. The ectodomain forms homodimers via the
membrane-distal IgI and IgII domains, resulting in a model for
OCAM-mediated cell-cell adhesion with an intercellular distance
of 20 nm.RESULTS
Crystal Structures of the Extracellular Domains
of OCAM
The crystal structures of recombinant proteins corresponding to
the IgI–II, IgII–III, IgI–III, IgIII–IV, IgIV–F3I, and IgIV–F3II domains
of human OCAM have been determined (Figures 2–4 and
Table 1). The structures of IgI, IgII, and IgIII all fall into the inter-
mediate 1 (I1) subset of Ig domains (Wang and Springer, 1998).
Overall, these three domains are structurally similar to those of
NCAM1, with root-mean-square deviations (rmsds) on Ca atoms
ranging from 0.6 to 0.9 A˚. However, important differences exist
between the structures of the Ig domains from NCAM1 and
OCAM. A C0 strand that is present in OCAM IgII (Figures 1 and
3) is missing in the corresponding NCAM1 IgII region, a region
known to be involved in heparin binding (Kulahin et al., 2005b;
Nielsen et al., 2010; Reyes et al., 1990). Consequently, the
heparin-binding site of NCAM1 is not conserved between
the two proteins (Figure 1). Moreover, the conformations of
the loop regions corresponding to the NCAM1 heparin-binding
sequence are very different between NCAM1 and OCAM, andights reserved
Figure 2. Overview of NCAM1 and OCAM Structures
(A) Schematic representation of NCAM1 and OCAM organization and of
recombinant OCAM proteins presented in this study. Tilt/twist angles are
shown above/below the constructs. The interdomain geometry was deter-
mined according to Bork et al. (1996). The tilt and twist angles were determined
by calculating planes through the b strands in each domain, and the z axis was
defined as passing along the long axis of the molecule. Corresponding
b strands in the Ig domains in question were superimposed on each other,
and the angle of rotation around the z axis required to superimpose the calcu-
lated planes of the domains was defined as the twist angle. The tilt angle was
defined as the angle between the z axes of the two domains.
(B) Schematic representation of NCAM1 IgI-II (PDB code 1epf) and IgI–III (PDB
code 1qz1) domains with tilt/twist angles shown above/below the constructs.
Figure 3. Structures of Recombinant OCAM IgI–II, IgI–III, and IgII–III
(A) Structures of recombinant OCAM IgI–II (PDB code 2XY2), IgI–III (PDB code
2wim), and IgII–III (PDB code 2v5t) with the intermolecular IgI–II angles
indicated. The corresponding angles in NCAM1 structures are given in
parentheses. N-linked glycosylation sites are shown as sticks and colored
red. Residues of the IgII domain of OCAM, corresponding to the heparin-
binding site in NCAM1 (Lys152-Arg156, Val158, Ile159, Lys161-Phe166,
Gly185, Tyr187, Glu190 in NCAM1; Uniprot code P13591), are shown as sticks
and colored orange.
(B) IgI–II dimer interfaces. The IgI–II dimer interface in the IgI–II structure is
shown on the left (with twomonomers colored in green and blue, respectively);
the IgI–II dimer interface in the IgI–III structure is shown in the middle (with two
monomers colored in green and blue, respectively). On the right, the two dimer
interfaces are superimposed with the IgI–II dimer interface derived from the
IgI–II in red and the dimer interface from the IgI–III structure in blue. See also
Figures S1, S3, and S4, and Tables S1 and S2.
Structure
Structural Model of the Entire Ectodomain of OCAMbecause the residues Glu153 and Glu154 (Uniprot codeO15394)
are disordered in the OCAM IgI–II, IgII–III, and IgI–III structures,
this region may be more flexible in OCAM than in NCAM1.
The loop connecting the IgIII C and D strands is three residues
shorter in OCAM than in NCAM1. Whereas this loop is disor-
dered in the NCAM1 IgI–III structure, it is clearly defined in the
OCAM IgI–III, IgII–III, and IgIII–IV structures. This ordering may
be related to the hydrogen bond formed between Tyr257 N
and Asn254 O. Notably, OCAM IgIV appears to belong to the
variable (V) subset of Ig domains due to the presence of a puta-
tive C00 strand. However, whereas the C00 strand is well defined in
the IgIII–IV structure, it is disordered in the IgIV–Fn3I and IgIV–
Fn3II structures. The loop region 346-GDKS-349 is one of the
most flexible regions in IgIV, and it is disordered in the OCAM
IgIV–Fn3I and IgIV–Fn3II structures. This loop corresponds to
the sequence in NCAM1 IgIV encoded by the VASE mini-exon
(354-ASWTRPEKQE-363) (Figure 1), which in NCAM1 is associ-
ated with downregulated neural plasticity (reviewed in Owczarek
et al., 2009). The IgV structure is most closely related to the
OCAM IgIII structure, with a Z-score of 13.1 and an rmsd of
1.9 A˚ using the DALI server (Holm et al., 2008), thus placing it
in the I1 subset of the Ig domains.
A DALI search revealed that the OCAM Fn3I structure is most
closely related to the NMR structure of the same domain (PDBStructure 19, 20code 2doc), with an rmsd of 0.8 A˚. It is also very similar to Fn3I
and Fn3II of NCAM1 (Carafoli et al., 2008; Kiselyov et al., 2003;
Mendiratta et al., 2006), with rmsds of 1.1 and 1.2 A˚, respec-
tively. The structure of OCAM Fn3II is most similar to the NMR
structure of the same domain (PDB code 2kbg), with an rmsd
of 1.1 A˚.Glycosylation of OCAM
Human OCAM contains eight potential sites for N-linked glyco-
sylation, five of which are also found in NCAM1 (Figures 1 and
5). However, in contrast to NCAM1, OCAM has been reported
not to be glycosylated with the unusual carbohydrate polysialic
acid (PSA; long, negatively charged homopolymer of a2-8-N
acetylneuraminic acid). N-linked glycosylation was clearly visible
at Asn177 in IgII, Asn219 in IgIII, Asn309 in IgIV, and Asn419,
Asn445, and Asn474 in IgV and could be unambiguously fitted
into the electron densities. The Asn177 glycosylation site is
absent in NCAM1, due to the presence of lysine at this position.
Glycosylation sites Asn445 and Asn474 in OCAM IgV, corre-
sponding to the polysialylation sites in NCAM1, are shown in
Figures 1, 4, and 5. Notably, the a helix between strands D and
E in the NCAM1 Fn3I domain (562-AKEASMEG-569; Figure 1),3–211, February 9, 2011 ª2011 Elsevier Ltd All rights reserved 205
Figure 4. Structures of Recombinant OCAM IgIII–IV (PDB Code
2XY1), IgIV–Fn3I (PDB Code 2XYC), and IgIV–Fn3II (PDB Code 2jll)
N-linked glycosylation sites are shown as sticks and colored red. OCAM resi-
dues polysialylated in NCAM1 are shown in purple, and the region in OCAM
Fn3I, corresponding to the a helix in NCAM1 critical for polysialylation, is
shown in orange. Residues indicating the position of the NCAM1 region
encoded by VASE exon are shown in blue. See also Figures S2 and S3, and
Tables S1 and S2.
Structure
Structural Model of the Entire Ectodomain of OCAMwhich has been shown to be implicated in polysialylation of the
NCAM1 IgV domain (Colley, 2010; Mendiratta et al., 2006), is
not present in OCAM, and indeed OCAM has been reported
not to be polysialylated (Yoshihara et al., 1997).Interdomain Arrangements
The link region between OCAM IgI and IgII appears almost linear,
with tilt and twist angles of 4–12 and 144–149, respectively
(Figure 2A). The most prominent interdomain interaction
observed is a hydrophobic stacking of Arg193 and Tyr112.
Arg193 also forms hydrogen bonds to the carbonyl oxygen
atoms of residues Gln113 and Ser141. Altogether, this arrange-
ment appears to confer rigidity to the linking region between the
two domains. A similar stacking interaction is found in the
NCAM1 structure, where the corresponding arginine forms an in-
terdomain salt bridge to Glu30 (Uniprot code P13596). With a tilt
angle of 28–31, IgII and IgIII are positioned in a near-linear
arrangement. The conformation is stabilized by interdomain
hydrogen bonds and salt bridges. Glu125 forms a salt bridge
to Lys286, and the side chain of Lys127 forms a hydrogen
bond to the carbonyl oxygen atom of Ala287. The tilt angle in
OCAM IgII–III is very similar to that of NCAM1. A salt bridge
between OCAM residues Glu125 and Lys127 is also seen in
NCAM1 (Glu128 and Lys293). The equivalent of the hydrogen
bond between OCAM residues Lys127 and Ala287 is also
formed in NCAM1 between Lys130 and Ala294. The OCAM IgIII
G strand and the IgIV A strand form one long strand in the struc-
ture. Along with the interdomain hydrogen bond formed between
residues Arg224 and Gln301, this long strand may stabilize the
domain interface at a twist angle of 24. Similarly, the OCAM
IgIV G strand is extended into the IgV domain, where it forms206 Structure 19, 203–211, February 9, 2011 ª2011 Elsevier Ltd All rone long b strand together with the A strand of IgV. Many other
interdomain interactions between IgIV and IgV are present,
including hydrogen bonds between Asp396 and Asn427,
Glu398 and His480, and Glu398 and Asn427. The observed tilt
angle is 27–28, again corresponding to a near-linear arrange-
ment of the domains.
The interdomain link between IgV and Fn3I in the OCAM IgIV–
Fn3II structure is more bent than the linker regions between Ig
domains, with a tilt angle of 52. One interdomain hydrogen
bond between Trp413 and Gly524 stabilizes the interface. The
only other interdomain interaction observed is a hydrophobic
stacking of Trp413 and Lys575. IgIV and IgV of the IgIV–Fn3I
structure have fold and interdomain link-region interactions
that are very similar to those observed in the IgIV–Fn3II struc-
ture. However, the IgV–Fn3I link is significantly different in the
two structures. The presence of a HEPES molecule appears to
play an important role in stabilizing the conformation between
IgV and Fn3I in this crystal structure (see Figure S2 available
online). The HEPES molecule makes hydrophobic contacts
with Tyr411, Ala493, Asp494, Val495, Pro496, Ser497, Ser498,
and Val525, and the complex is further stabilized by hydrogen
bonds through two water molecules. The observed tilt angle
between Fn3I and Fn3II is 57. When examining the linkage
between Fn3I and Fn3II, no hydrogen bonds or other types of
interactions are evident.
Molecular dynamics simulations were conducted on a number
of recombinant OCAMproteins. Ten-nanosecond simulations on
monomeric IgI–III domains showed several large folding and
twisting motions around the hinges between the domains. The
movements around the IgI–II hinge were significantly larger
than the movements around the IgII–III hinge, and the tilt angles
of the domains varied from 12 to 73 around the IgI–II hinge
(compared with only 28–44 for the IgII–III hinge) (Table S1).
Two simulations of IgIV–Fn3I with and without the HEPES
molecule showed significant differences. The simulation with
the HEPES molecule bound to the protein only showed small
variations compared with the crystal structure, and the simula-
tion without HEPES displayed significant movement of the
domains. During this simulation the tilt angle between the IgV
and Fn3I domains changed from 98 (similar to the crystal struc-
ture) toward an equilibrium value of 65 (which is close to the tilt
angle observed in the IgIV–Fn3II structure). The amino acids
Leu395, Asp396, Leu490, Ala491, and Leu492 have been identi-
fied (by analysis backbone torsional angle changes) as being
primarily responsible for the change in the tilt angle. The differ-
ence between the two simulations of IgIV–Fn3I with and without
the HEPES molecule indicates flexibility in the IgV–Fn3I linker
region and that the HEPES molecule is stabilizing the conforma-
tion observed in the crystal structure.
The simulations of the IgIV–Fn3II structure (four domains and
three hinges) showed some flexibility of the hinges, with the
Fn3I–Fn3II hinge being most flexible. Thus, the tilt angle between
IgIV and IgV varied from 24 to 27, between IgV and Fn3I from
50 to 52, and between Fn3I and Fn3II from 57 to 82. During
the simulations, no conformations were even remotely similar
to the IgIV–Fn3I structure with a HEPES molecule bound. Thus,
analysis of the longest recombinant OCAM proteins indicated
that most of the flexibility of the OCAM ectodomain originates
from the IgI–II hinge.ights reserved
Table 1. Data Collection and Processing Statistics for OCAM IgI–II, IgII–III, IgI–III, IgIII–IV, IgIV–Fn3I, and IgIV–Fn3II
Construct OCAM IgI–II OCAM IgII–III OCAM IgI–III OCAM IgIII–IV OCAM IgIV–F3I OCAM IgIV–F3II
X-ray source I911-2, MAX-Lab,
Lund, Sweden
ID23-1, ESRF,
Grenoble, France
ID29, ESRF,
Grenoble, France
ID23-2, ESRF,
Grenoble, France
I911-5, MAX-Lab,
Lund, Sweden
ID29, ESRF,
Grenoble, France
Wavelength (A˚) 1.041 0.979 0.976 0.873 0.908 0.976
Space group P3121 P41212 P212121 P21 P43212 C2
Unit-cell parameters
a (A˚) 42.06 114.95 38.39 43.81 139.66 151.74
b (A˚) 42.06 114.95 106.78 45.81 139.66 33.80
c (A˚) 202.91 46.00 188.74 45.72 47.79 97.67
b () – – – 103.58 – 98.36
Resolution (A˚) 28.99–1.82
(1.87–1.82)
20.0–2.00
(2.11–2.00)
24.57–3.00
(3.08–3.00)
20.2–1.98
(2.03–1.98)
62.46–2.51
(2.57–2.51)
19.79–2.30
(2.42–2.30)
Number of unique
observations
19,558 21,021 15,703 12018 16752 38513
Redundancy 4.6 (4.5) 5.9 (6.1) 4.7 (4.7) 3.7 (3.6) 7.1 (7.2) 3.7 (3.8)
Completeness (%) 99.5 (95.9) 98.7 (98.7) 91.9 (96.1) 96.8 (90.9) 99.9 (100) 90.4 (99.9)
I/s(I) 23.1 (3.0) 15.60 (2.80) 16.60 (3.80) 10.40 (2.6) 14.60(2.90) 8.60 (2.30)
Rsym (%)
a 3.5 (50.4) 9 (25) 6 (39) 8.5 (58.9) 10.1 (72.6) 4.2 (27.2)
Refinement
Rwork (%)
b 20.3 18.2 21.3 20.0 19.4 21.6
Rfree (%)
c 24.0 23.4 28.7 26.6 24.1 26.9
Total atoms 1,696 1,730 4,283 1,647 2,594 3,241
Protein 1,501 1,458 4,209 1,526 2,339 3,031
Water 175 210 31 93 183 147
Ligands 20 62 43 28 72 63
Rmsd bond lengths (A˚) 0.007 0.005 0.006 0.007 0.008 0.004
Rmsd bond angles () 1.052 0.732 0.978 1.149 1.157 0.921
Mean B (A˚2) 35.3 26.5 96.58 39.7 51.3
Ramachandran plot (%)d 92.4; 6.4; 1.2; 0.0 90.0; 10.0; 0.0; 0.0 76.3; 20.8; 2.1; 0.8 91.5; 7.9; 0.6; 0.0 87.4; 11.9; 0.4; 0.4 88.6; 10.5; 0.9; 0.0
Values in parentheses are for the highest resolution shell.
a Rsym =
P
hkl (
P
i[jIhkl, i  <Ihkl> j])/
P
hkl, i <Ihkl, i> , where Ihkl, i is the intensity of an individual measurement of the reflection with Miller indices h, k, and l,
and <Ihkl> is the mean intensity of that reflection.
bRwork =
P
hkl (kFo, hklj  jFc, hklk)/jFo, hklj, where jFo, hklj and jFc, hklj are the observed and calculated structure factor amplitudes.
c Rfree is equivalent to Rwork but calculated with reflections omitted from the refinement process (5% of reflections omitted).
d Percentage of total number of residues in the ‘‘favoured,’’ ‘‘allowed,’’ ‘‘additionally allowed,’’ and ‘‘disallowed’’ regions, respectively, of the Rama-
chandran plot according to PROCHECK definitions (Laskowski et al., 1993).
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The IgI–II and IgI–III structures reveal one significant protein-
protein interface with an area of 980 A˚2 in the IgI–II structure
with ten hydrogen bonds and six salt bridges in the interface
(residues involved in dimerization can be seen in Figure 1). In
the IgI–III structure the interface area is only 620 A˚2, possibly
due to a smaller angle between the molecules constituting the
dimer than in the IgI–II dimer (113 versus 133) (Figure 3A).
The dimer interfaces obtained from the IgI-II and IgI-III struc-
tures, respectively, are shown in Figure 3B. Approximately
80% of the residues involved in this dimer interface are
conserved between NCAM1 and OCAM (Figure 1), and the
OCAM interface is very similar to that observed in the NCAM1
IgI–II and IgI–III structures (Colley, 2010; Kasper et al., 2000; Sor-
oka et al., 2003). Analysis of the crystal packing interactions in
the four other structures did not reveal any other significant
interfaces.Structure 19, 20To investigate the IgI–IgII dimerization in solution, gel filtration
chromatography was applied. The protein eluted as one peak at
an elution time corresponding to the dimeric form of the protein
(Figure S3A). Moreover, OCAM IgI–III, comprising 291 amino
acids, eluted as a protein with a higher molecular weight than
OCAM IgIV–Fn3II, comprising 400 amino acids (Figure S3B),
indicating that IgI–III dimerizes in solution. To further investigate
the structure of OCAM IgI–III in solution, the protein was sub-
jected to small-angle X-ray scattering (SAXS) analysis. The
molecular weight of the solute was estimated to be 72 kDa, cor-
responding to the expected molecular weight of a dimer
(69 kDa). The pairwise distance distribution function (P[r]) derived
from the solution-scattering curve (Figure S4) indicates
a maximal dimension of the protein dimer of 150 A˚. This dimen-
sion is significantly larger than the maximal distances observed
within the crystal structure of the IgI–III dimer (130 A˚). The
modular buildup of the dimer is evident from the P(r), which3–211, February 9, 2011 ª2011 Elsevier Ltd All rights reserved 207
Figure 5. Structural Model of the Entire OCAM Ectodomain Built
from the Overlapping IgI–II, IgII–III, IgIII–IV, and IgIV–Fn3II Structures
On the model, N-glycosylations are modeled as the complex sialylated fuco-
sylated triantennary type. The glycosylation corresponding to the position of
the polysialylation in NCAM is colored orange. The rest of the glycosylations
are colored red. See also Figures S1 and S3.
Structure
Structural Model of the Entire Ectodomain of OCAMclearly shows the presence of a typical distance around 20 A˚,
corresponding to the radius of gyration (Rg) of an Ig domain.
An ab initio beadmodel can be fitted by the IgI–IgIII crystal struc-
ture in which the intermolecular angle (angle between molecules
in the dimer) is opened an additional 28.
Structural analysis of the dimerization site indicated that
Leu27, Phe39, and Arg77 contribute significantly to the interac-
tion interface. To verify the role of these amino acids, the
following two double mutants were produced: Leu27Ser +
Phe39Ser (IgI–IILF) and Phe39Ser + Arg77Glu (IgI–IIFR). Both
proteins eluted as broad peaks, corresponding to combined
monomeric and dimeric forms of the proteins, whereas the intact
protein eluted as a single peak at elution time corresponding to
the dimeric form (Figure S3A). Therefore, the introduced muta-
tions partly disrupt the IgI–IgII dimer interface.
Structural Model of the Ectodomain
A model of the entire extracellular part of OCAM was built from
overlapping IgI–II, IgII–III, IgIII–IV, and IgIV–Fn3II structures (Fig-
ure 5). The model represents a complete dimer of the OCAM
ectodomain interpreted as a trans-interacting homodimer with
a cell-to-cell distance of about 20 nm.
DISCUSSION
To understand the structural context for homophilic binding of Ig
CAMs, we previously attempted to crystallize NCAM1 and L1 ec-
todomain fragments consisting of more than four domains, but
these crystals only diffracted to low resolution (Kulahin et al.,
2004, 2005a). In the present study we chose another strategy
and crystallized several overlapping constructs of the OCAM ec-
todomain. This approach allowed the construction of a structural
model of the entire ectodomain based on six overlapping struc-
tures of truncated versions of the protein. Altogether, the high
consistency in tilt and twist angles (Figure 2A) in combination208 Structure 19, 203–211, February 9, 2011 ª2011 Elsevier Ltd All rwith the results of the molecular dynamics simulations support
the notion that the average conformations of the various re-
combinant OCAM proteins resemble the conformations seen in
the crystals. Consequently, a structural model of the entire
OCAM ectodomain was assembled from the crystallized over-
lapping modular constructs. The model is shown in Figure 5. It
consists of an essentially linear segment composed of the
IgI–V domains, followed by bent hinges between the IgV and
Fn3I domains and between the Fn3I and Fn3II domains. The tilt
and twist angles in IgI–II and IgI–III are comparable to the angles
observed in NCAM1 (Figure 2B) (Kasper et al., 2000; Soroka
et al., 2003). Furthermore, the angles between IgI and IgII are
also within the same range as the angles observed in the crystal
structures of VCAM IgI–II (Wang et al., 1995) and the EC domains
in N- and E-cadherin (Koch et al., 1999). These findings further
support a model in which the entire OCAM IgI–V segment can
adopt an essentially linear conformation, with variations of only
10–15 in the hinges.
The bend between OCAM IgV and Fn3I in the IgIV–Fn3I struc-
ture is caused by a HEPES molecule bound in the hinge region,
and the structure can represent one of several OCAM conforma-
tions. This is consistent with findings from electron microscopy
that identified a hinge region around IgV in NCAM1 (Hall and
Rutishauser, 1987). The bend between OCAM IgV and Fn3I is
less pronounced in the OCAM IgIV–Fn3II structure. However,
models of the entire ectodomain based on the IgIV–Fn3I struc-
ture (with a tilt angle of 98) and the IgIV–Fn3II structure (with
a tilt angle of 52) result in approximately the same intercellular
distances, and both models imply that the Ig domains can be
positioned parallel with and in quite close proximity to the cell
surface. The residues that interact with the HEPES molecule
are conserved between NCAMs from several species (Figure S2)
and may, therefore, form a regulatory binding site that is func-
tionally important for all NCAMs.
The analysis of the IgIV–Fn3II structure did not reveal any inter-
domain interactions between the Fn3 domains, which together
with the results from the molecular dynamics simulations indi-
cate that the hinge region between these domains is one of the
flexible regions in the OCAM ectodomain. This interpretation is
supported by the structure of NCAM1 Fn3I–II, which also indi-
cates that the link between the NCAM1 Fn3I and Fn3II is flexible
(Carafoli et al., 2008).
Protein-protein interactions in crystals may represent biologi-
cally important interactions, and several publications have
shown that biologically important adhesion interactions can be
found in the crystalline phase, although they are not detected
in solution (Freigang et al., 2000). A recent structure model of
OCAM IgI suggested that this module exhibits domain swapping
created by an interchange of the N-terminal A1 b strands
(Rasmussen et al., 2008). However, in the present study, neither
the IgI–II nor the IgI–III structure demonstrated any domain
swapping between the IgI domains, and in the six OCAM struc-
tures presented in this study, the IgI–II dimerization was the only
homophilic interaction observed in more than one crystal struc-
ture. This interface is composed of essentially three linear
epitopes, formed by residues equivalent to residues forming
the IgI–II dimer in NCAM1 (Figure 1). Five interface residues
(Lys38, Phe39, Thr79, Tyr81, and Arg189) are conserved
betweenNCAM1 andOCAM, suggesting that they play a primaryights reserved
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Glu191 residues of OCAMmay provide specificity for homophilic
binding. These residues correspond to Leu40, Thr80, and
Leu194 in NCAM1, and these differences in the protein
sequence may explain why NCAM1 and OCAM do not bind
each other (Yoshihara et al., 1997). The angles between the
molecules comprising the NCAM1 and OCAMdimers (Figure 3A)
suggest plasticity of the dimer interface. This is especially
pronounced in OCAM, where the intermolecular angles derived
from the IgI–II and IgI–III structures differ by 20. The difference
in the angle can probably be explained by different crystal
packing of the proteins. Solution-scattering experiments
suggest even more pronounced plasticity of the dimer interface
(Figure S4). Molecular dynamics simulations indicate that the
IgI–II hinge is one of themost flexible ectodomain regions, further
supporting the dependence of the intermolecular angle on the
conformational restrictions on the protein (crystal versus solution
conformation). The flexibility of the IgI–II hinge might be neces-
sary for conformational adaptation during OCAM dimerization
and is probably reduced after the dimer formation, resulting in
a linear conformation of the region.
NCAM1-mediated homophilic cell adhesion has been the
topic of several studies (reviewed in Soroka et al., 2010). The first
models, based on cell or microsphere aggregation techniques,
suggested that the IgIII domain mediated the trans-homophilic
interaction (Rao et al., 1992). Later, an IgI-IgII interaction was
detected by surface plasmon resonance (Kiselyov et al., 1997),
and this gave rise to a model in which trans-homophilic binding
was mediated by IgI–II dimerization. The most recent model is
based on the crystal structure of NCAM1 IgI–III (Soroka et al.,
2003). Interestingly, this model interprets the IgI–IgII interaction
as a cis-interaction, whereas homophilic NCAM1 trans-interac-
tions are mediated by zipper-like interactions among IgI–IgIII,
IgII–IgIII, and IgII–IgII (Figure S1). In contrast the results pre-
sented in this study clearly suggest that in OCAM the IgI–IgII
interaction represents a trans-interaction (Figure 5), whereas
no homophilic cis-interactions were identified.
In conclusion the presented structural model of OCAM
suggests that the molecule forms trans-homophilic dimers
through reciprocal IgI-IgII interactions, and that the Ig domains
form a linear segment positioned parallel to the cell surface, fol-
lowed by bends in the more membrane-proximal part of the
molecule. Moreover, the majority of the flexibility of the structure
seems to be restricted to the membrane-proximal hinges of the
molecule, and to the IgI-IgII dimerization interface. The spatial
arrangement may facilitate heterophilic interactions between
the OCAM ectodomain and unidentified counter-receptors.
Whereas little is known about OCAM interactions, NCAM1 is
known to form numerous extracellular heterophilic interactions,
including interactions between the NCAM1 Fn3 domains and
the fibroblast growth factor receptor and interactions with
several extracellular matrix molecules (Nielsen et al., 2010;
Walmod et al., 2004).
The model of the OCAM ectodomain described here implies
that homophilic OCAM interactions lead to an intercellular
distance of about 20 nm. This intercellular distance is compa-
rable to the 14 nm intercellular distance recently reported for
the trans-heterophilic SIRPa-CD47 interaction (Hatherley et al.,
2009). In support of these models, such distances between cellStructure 19, 20membranes are observed in chemical synapses (Hormuzdi
et al., 2004).
EXPERIMENTAL PROCEDURES
Protein Cloning and Expression
Constructs encoding recombinant protein were prepared using polymerase
chain reaction amplification of human NCAM2 cDNA (Ensembl Gene ID
ENSG00000154654; RZPD, Germany) for subcloning into the ClaI/NotI sites
of the pPICZa C plasmid (Invitrogen). All recombinant proteins consist of
two N-terminal residues (Ser and Met) remaining from the cloning procedure,
followed by amino acids from various recombinant human OCAM proteins
(Swiss-Prot code O15394) and six C-terminal histidine residues. The IgI–II
construct comprises amino acids 19–218, IgII–III amino acids 115–301, IgI–
III amino acids 19–301, IgIII–IV amino acids 209–400, IgIV–Fn3I amino acids
302–593, and IgIV–Fn3II amino acids 302–693. Two double mutants of IgI–II
(IgI–IILF and IgI–IIFR) were produced using a Phusion Site-Directed Muta-
genesis Kit (Finnzymes). Mutations Leu27Ser and Phe39Ser and mutations
Phe39Ser and Arg77Glu were introduced into the OCAM IgI–IILF and OCAM
IgI–IIFR mutants, respectively. All constructs were verified by DNA
sequencing. The recombinant plasmids were linearized with SacI enzyme
and used for transformation of the Pichia pastoris strain KM71H (Invitrogen).
Transformation and selection were performed by the protocol supplied by
the manufacturer. A preinduction culture was grown for 48 hr in BMGH
medium before transfer and continued growth and induction in BMMH
medium for 24 hr. The secreted proteins were purified using Ni-NTA (QIAGEN)
affinity chromatography. All proteins were deglycosylated using Endo Hf (New
England Biolabs). As a final purification step, gel filtration chromatography was
performed either in phosphate-buffered saline (PBS; Sigma; for SAXS experi-
ments and analytical gel filtration chromatography) or 10 mM HEPES (Sigma)
(pH 7.4), 20 mM NaCl (Sigma; for X-ray crystallography experiments). All
protein constructs were concentrated to 3–8 mg/ml using Amicon Centrifugal
Filter Units (Millipore).
Gel Filtration Chromatography
Gel filtration chromatography was performed with a HiLoad 16/60 Superdex
200 prep grade column (GE Healthcare) connected to an A¨kta FPLC system
(GE Healthcare). The flow rate was 1 ml/min, and the temperature was
5C–6C in all experiments. The column was equilibrated with PBS (pH 7.4)
or 10 mM HEPES (pH 7.4), 20 mM NaCl. The column was calibrated in PBS
(Figure S2C). The calibration set (GE Healthcare) included blue dextran 2000
(2000 kDa), thyroglobulin (669 kDa), ferritin (444 kDa), aldolase (158 kDa),
conalbumin (75 kDa), ovalbumin (43 kDa), and chymotrypsinogen A (25 kDa).
Two milliliters of protein were injected onto the column.
Crystallization and Crystal Structure Determinations
Crystallization was achieved by hanging-drop experiments by mixing 1 ml
protein and 1 ml reservoir solution (30% PEG-4000, 0.2 M sodium acetate tri-
hydrate, 0.1 M tris hydrochloride [pH 8.5], for IgI–II; 30% PEG-4000, 0.2 M
lithium sulfate, 0.1 M tris hydrochloride [pH 8.5], for IgII–III; 25% PEG-6000,
0.1 M HEPES [pH 7.0], for IgIII–IV; 4% PEG-3350, 0.02 M calcium chloride,
0.1 M citric acid [pH 4.5], for IgI–III; 10% PEG-3350, 0.1 M ammonium
phosphate, 0.01 M trimethylamine hydrochloride for IgIV–Fn3I; and 14%
PEG-10000, 0.2 M calcium acetate, 0.1 M HEPES [pH 6.5], for IgIV–Fn3II).
All chemicals were purchased from Sigma-Aldrich. Diffraction data on all six
truncations of OCAM were collected at 100 K. Details of data collection and
processing are presented in Table 1. The structures were determined by the
molecular replacement method using the program PHASER (Storoni et al.,
2004). Details on the models used for the molecular replacement method
are provided in the Supplemental Experimental Procedures. Model building
was performed using the program ARP/wARP (Perrakis et al., 1999) and
manual correction using the program COOT (Emsley and Cowtan, 2004).
The program PHENIX (Adams et al., 2002) was used for refinement, and the
quality of the final structures was examined using PROCHECK (Laskowski
et al., 1993). Analysis of binding interfaces was performed using PISA server
(http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html, accessed November 28,
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Molecular dynamics simulations were performed with the Amber software
suite, version 8 (Case et al., 2005). Parameters were from the Amber99 force
field (Wang et al., 2000) for all molecules, with the exception that the NAG
and HEPES molecules in model IgIV–Fn3I used the parameters from the gaff
force field (Wang et al., 2004).
The complexes were solvated in octahedral boxes of water molecules,
extending at least 8 A˚ outside the protein. Hydrogen atoms and water mole-
cules were added using the LEaP module in Amber, assuming that all Asp
and Glu residues were negatively charged and that the Lys and Arg residues
were positively charged.
The solvent and hydrogen atoms were relaxed by a short molecular
mechanics minimization (100 steps), followed by 20 ps molecular dynamics
simulation. After relaxation, the entire system was equilibrated by 50 ps of
constant pressure simulations, followed by 200 ps of constant volume simula-
tions. Finally, a production simulation of 10 ns was performed for each system.
All simulations were performed using a time step of 2 fs. Additional details are
provided in the Supplemental Experimental Procedures.
Solution SAXS
SAXS data collection was performed at beamline I711 (MAXlab, Lund,
Sweden) in the momentum transfer range 0.010 < s < 0.325 A˚1 (s = 4p
sinq/l, where q is half the scattering angle) using a wavelength of 1.05 A˚
and a MAR165 CCD detector. The sample exposure time was 10 min. Buffers
were measured before and after sample exposure and averaged before back-
ground subtraction. Repeated exposure did not reveal any radiation damage.
BioXTAS RAW (Toft et al., 2008) software was used for radial averaging and
background subtraction. The average molecular mass of the protein was
estimated from the extrapolated forward scattering I(0) by using a reference
solution of bovine serum albumin. The data were fitted to theoretical scattering
curves of relevant structures using the program CRYSOL (Svergun et al.,
1995). The indirect Fourier transform program GNOM (Svergun, 1992) calcu-
lated the P(r) and estimated the average Rg and the maximal distance (Dmax)
within the scattering protein. The program DAMMIF (Franke and Svergun,
2009) was applied to calculate ab initio bead models, representing the overall
solution conformation. Starting parameters for themodeling was a sphere with
a diameter of 160 A˚, using standard settings. P2 symmetry was evident from
the initial run, and 20 models were correspondingly calculated by applying
symmetry. These models were averaged and filtered to the final model in the
program DAMAVER (Volkov and Svergun, 2003).
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